InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
August 07 2008 - 9:15AM
PR Newswire (US)
BRITISH COLUMBIA, Canada, Aug. 7 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF)
(http://www.ixsbio.com/), a drug development company
commercializing the next generation of monoclonal antibodies based
on its Dynamic Cross Linking (DXL(TM)) technology, announced today
that it has launched a large scale primate study of DXL625 (CD20),
the company's lead program. "We are beginning a study in cynomolgus
monkeys of DXL625, an antibody directed against the B-cell marker
CD20 and enhanced in potency with our DXL(TM) technology," said
Thomas Kindt, Ph.D., Chief Scientific Officer. "The test is
designed to evaluate toxicity and pharmokinetics of our product and
to measure B-cell depletion and recovery in this primate species.
This study, which takes multiple months to complete and is part of
our drug development plan will generate data moving us toward human
clinical trial testing with DXL625." "Our scientific team has made
steady progress in the rapid development of our first preclinical
candidate, DXL625 for the prospective treatment of Non-Hodgkin's
Lymphoma," said Jeff Morhet, CEO and Chairman. "The primate study
is being conducted by Covance Inc. within their world-class
facilities in Wisconsin. The launch of this study marks a
significant milestone achievement for the company and our lead
product DXL625." InNexus recently announced the addition of a new
product designated DXLr120 (CD20). This is the third product added
to the growing InNexus pipeline and was developed using new
recombinant methods to produce a DXL(TM) anti-CD20 antibody. Upon
questions regarding InNexus having a franchise of CD20 products
using multiple methods of creation, chemical and recombinant, CEO
Morhet said, "I would also think that these products could and
should be bundled toward future collaborations with pharmaceutical
companies and DXLr120 was developed within our partnership with
Royalty Pharma." About InNexus InNexus is a drug development
company commercializing the next generation of monoclonal
antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and
disease applications. DXL(TM) antibodies utilize unique, novel and
patented methods and technologies of InNexus. InNexus is
headquartered in British Columbia with principal management based
in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources
provide validation of protein and peptide discoveries, enabling
InNexus (and its strategic partners) to advance novel drug
therapeutics and diagnostics. To learn more about InNexus, please
visit http://www.ixsbio.com/. The TSX Venture Exchange has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this news release. This news release may contain
assumptions, estimates, and other forward-looking statements that
involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, that may
cause actual results or performance to differ materially from those
currently anticipated in such statements. DATASOURCE: InNexus
Biotechnology Inc. CONTACT: Jeff Morhet, Chairman & Chief
Executive Officer, or Dr. Thomas Kindt, Chief Scientific Officer,
both of InNexus Biotechnology Inc., +1-480-862-7500 Web site:
http://www.ixsbio.com/
Copyright